CN115504913A - 一种阿维巴坦钠中间体的合成方法 - Google Patents
一种阿维巴坦钠中间体的合成方法 Download PDFInfo
- Publication number
- CN115504913A CN115504913A CN202110695178.2A CN202110695178A CN115504913A CN 115504913 A CN115504913 A CN 115504913A CN 202110695178 A CN202110695178 A CN 202110695178A CN 115504913 A CN115504913 A CN 115504913A
- Authority
- CN
- China
- Prior art keywords
- reaction
- carbon dioxide
- dioxide gas
- avibactam sodium
- sodium intermediate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RTCIKUMODPANKX-JBUOLDKXSA-M avibactam sodium Chemical compound [Na+].NC(=O)[C@@H]1CC[C@H]2N(OS([O-])(=O)=O)C(=O)N1C2 RTCIKUMODPANKX-JBUOLDKXSA-M 0.000 title claims abstract description 12
- 229960001496 avibactam sodium Drugs 0.000 title claims abstract description 11
- 238000010189 synthetic method Methods 0.000 title claims description 6
- 238000006243 chemical reaction Methods 0.000 claims abstract description 28
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims abstract description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000001569 carbon dioxide Substances 0.000 claims abstract description 8
- 229910002092 carbon dioxide Inorganic materials 0.000 claims abstract description 8
- 238000005406 washing Methods 0.000 claims abstract description 8
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims abstract description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000003513 alkali Substances 0.000 claims abstract description 5
- 235000011114 ammonium hydroxide Nutrition 0.000 claims abstract description 5
- 239000002585 base Substances 0.000 claims abstract description 5
- 238000007363 ring formation reaction Methods 0.000 claims abstract description 5
- 230000002194 synthesizing effect Effects 0.000 claims abstract description 5
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 claims abstract description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims abstract 6
- 238000004090 dissolution Methods 0.000 claims abstract 2
- 239000012295 chemical reaction liquid Substances 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 238000001308 synthesis method Methods 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- 230000007547 defect Effects 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 48
- 239000012074 organic phase Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 239000003781 beta lactamase inhibitor Substances 0.000 description 4
- 229940126813 beta-lactamase inhibitor Drugs 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000012452 mother liquor Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- IBSREHMXUMOFBB-JFUDTMANSA-N 5u8924t11h Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 IBSREHMXUMOFBB-JFUDTMANSA-N 0.000 description 2
- 239000005660 Abamectin Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 229950008167 abamectin Drugs 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000012527 feed solution Substances 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000007142 ring opening reaction Methods 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- -1 sulfoxide iodide Chemical class 0.000 description 2
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 description 2
- XQDYOPKCGHWFBY-UHFFFAOYSA-N 1-cyclooctyl-1,3-diazocan-2-one Chemical class O=C1NCCCCCN1C1CCCCCCC1 XQDYOPKCGHWFBY-UHFFFAOYSA-N 0.000 description 1
- YWWWGFSJHCFVOW-QMMMGPOBSA-N 1-o-tert-butyl 2-o-ethyl (2s)-5-oxopyrrolidine-1,2-dicarboxylate Chemical compound CCOC(=O)[C@@H]1CCC(=O)N1C(=O)OC(C)(C)C YWWWGFSJHCFVOW-QMMMGPOBSA-N 0.000 description 1
- TZNBTMCEMLXYEM-ZDUSSCGKSA-N 2-o-benzyl 1-o-tert-butyl (2s)-5-oxopyrrolidine-1,2-dicarboxylate Chemical compound C1CC(=O)N(C(=O)OC(C)(C)C)[C@@H]1C(=O)OCC1=CC=CC=C1 TZNBTMCEMLXYEM-ZDUSSCGKSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229960002379 avibactam Drugs 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- HYDZPXNVHXJHBG-UHFFFAOYSA-N o-benzylhydroxylamine;hydron;chloride Chemical compound Cl.NOCC1=CC=CC=C1 HYDZPXNVHXJHBG-UHFFFAOYSA-N 0.000 description 1
- GEVPUGOOGXGPIO-UHFFFAOYSA-N oxalic acid;dihydrate Chemical compound O.O.OC(=O)C(O)=O GEVPUGOOGXGPIO-UHFFFAOYSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C315/00—Preparation of sulfones; Preparation of sulfoxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明公开了一种阿维巴坦钠中间体的合成方法,属于药物合成领域。本发明的合成方法在第一步反应中使用碱为二(三甲基硅基)氨基锂)四氢呋喃溶液,反应为均相反应;在第三步成环反应中使用碱为氨水,无二氧化碳气体放出,避免反应二氧化碳气体放出导致的反应液溢出;在第四步拆分的后处理中用甲基叔丁醚洗涤产品,减少产品溶解。该方法避开了原有技术非均相反应,反应二氧化碳气体放出容易导致反应液溢出等缺陷。该方法反应操作方便,安全性高。
Description
技术领域
本发明属于药物合成领域,具体涉及一种阿维巴坦钠中间体的合成方法。
背景技术
阿维巴坦钠(Avibactam,, NXL-104)属于二氮杂双环辛酮化合物, 是目前最被看好的新型β-内酰胺酶抑制剂。与三种已上市的β-内酰胺酶抑制剂相比,具有长效和与酶可逆性共价结合,且不会诱导β-内酰胺酶产生的特点。
近年来国内抗生素项目投资遇冷,但实际情况是近年来的抗生素在医院的销售占比并未下降.与此同时“限抗令”导致抗生素临床应用发生结构性变化,含有β-内酰胺酶抑制剂的复方品种呈增长趋势。阿维巴坦钠的出现无疑给处于低谷的抗生素领域吹来一股新风。
化合物1为合成阿维巴坦钠的重要中间体,结构式如下:
1
化合物1文献合成路线以N-Boc-L-焦谷氨酸乙酯或苄酯为起始原料,经过开环,亲核取代,脱Boc, 环化,还原并拆分得到。
在第一步开环反应中使用氢化钠或叔丁醇钾等强碱,采用非均相反应,不利于传质,传热;在第三步成环反应中使用碳酸氢钾作为碱中和甲磺酸会有二氧化碳气体放出,容易导致反应体系溢出;在第四步拆分的后处理使用乙酸乙酯洗涤会溶解部分产品。例如:US2012323010 A1, EP 2657234 A1, CN 103649051 A,CN 106699756 A;
此外,专利CN 108822014 A以碳酸盐作为碱进行反应,由于其碱性弱,需要加热至50度,且反应时间长达21小时,在工业化放大生产时,容易产生难于控制的气体,降低了工业化生产安全性,增大反应后处理难度。
此外,专利CN 110590618 A以氢氧化锂或氢氧化镁作为碱进行反应,由于其碱性弱,仍然需要加热至30度,并且为非均相反应。
发明内容
为了解决上述问题,本发明提供一种阿维巴坦钠中间体的合成方法。
为了实现上述目的,本发明采用如下技术方案。
一种阿维巴坦钠中间体的合成方法,其特征在于,合成路线为:
上述阿维巴坦钠中间体的合成方法,具体包括如下步骤:
第一步反应使用碱为二(三甲基硅基)氨基锂)四氢呋喃溶液,反应为均相反应。
第三步成环反应中使用碱为氨水,无二氧化碳气体放出,避免反应二氧化碳气体放出导致的反应液溢出。
第四步拆分的后处理中用甲基叔丁醚洗涤产品,避免产物溶解。
具体实施方式
下面结合实施例对本发明作进一步的描述,以下实施例仅示例本发明,不应该理解为以任何方式限定本发明的范围,本领域的普通技术人员无创新性的其它实施例,都属于本发明的保护范围。
实施例:化合物1的制备
1. J003-2的制备:
在10±2℃,向2L四口瓶中加入二甲亚砜660g和三甲基碘化亚砜85.5g;加毕,降温至-11±1℃,滴加二(三甲基硅基)氨基锂)(1M in THF,430mL), 搅拌1.5小时后, 称取100g J003-1,控温-11±1℃加入前述反应体系中。加毕,保温-11±1℃搅拌约30~60分钟,期间以TLC监控至原料反应完(展开剂:乙酸乙酯/甲醇=20/1,产物Rf=0.25); 先后向体系中加入500g饱和氯化铵溶液,300g纯化水,889g乙酸乙酯。分液,取乙酸乙酯层。水层再以乙酸乙酯萃取(440g*5),合并有机相,以300g水洗3次,合并洗涤的水相并以300克乙酸乙酯洗涤一次。合并所有有机相,以不超过35℃蒸出乙酸乙酯和四氢呋喃回收利用。剩余物以800g乙酸乙酯搅拌溶清,以300g饱和食盐水洗涤后,上层有机相以无水硫酸钠干燥,过滤,母液浓缩至400毫升,直接用于下一步。
2. J003-3的制备:
洁净干燥2L四口瓶中加入上一步所得400毫升J003-2料液(取样1毫升备TLC监控用);加入O-苄基羟胺盐酸盐65g。加入乙酸乙酯622g。升温至78±2℃回流反应2小时,TLC监控至原料J003-2反应完(展开剂:乙酸乙酯:甲醇=20:1);降至25±2℃,以纯化水500g洗涤一次,饱和食盐水500g洗涤2次后,有机相以无水硫酸钠干燥,过滤,母液浓缩至500毫升,直接用于下一步。
3. J003-4的制备:
洁净干燥2L四口瓶中加入上一步所得J003-3乙酸乙酯料液(取样1毫升备TLC监控用);在10±2℃下滴加111.7g甲磺酸,有气泡冒出,控制温度不超过25℃。体系由澄清变浑浊,再变澄清;加热至43±2℃,保温反应45分钟,期间TLC监控反应至原料消失,产生中间体(展开剂:石油醚:乙酸乙酯=5:1),取样1毫升备TLC对比用;向反应体系慢慢加入氨水,测pH约8;升温至52±1℃搅拌反应1.5小时,期间测pH使之保持在8左右,TLC监控至中间体消失;降温至25±2℃,将分出的有机相用500g饱和食盐水洗涤后,有机相以无水硫酸钠干燥30分钟,过滤,母液浓缩至600毫升,直接用于下一步。
4.化合物1的制备:
洁净干燥2L四口瓶中加入717.6g乙酸乙酯,搅拌下加入28.75g硼氢化钠,降温至4±2℃;控温4±2℃滴加172.8g丙酸;滴毕,升温至10±2℃搅拌2h左右,体系溶清,备用;J003-4料液600毫升加入洁净干燥3L四口反应瓶中(留样1毫升备TLC监控用),降温至-20±2℃;控制温度-20±2℃,缓慢滴加190.4g浓硫酸,体系由浑浊逐渐变澄清;控制温度-20±2℃,将制备的三丙酰氧基硼氢化钠溶液缓慢滴入反应体系,体系逐渐析出大量固体;滴毕,保温-20±2℃搅拌1小时,期间TLC监控至J003-4反应完全;向体系中加入1200g冰冷纯水,分液,水相用360g乙酸乙酯洗涤1次后,将氨水滴入该水相,控温不超过10±2℃,至pH到11;用乙酸乙酯萃取(360g*2),合并有机相,用200g纯水洗涤1次;取有机相,以无水硫酸钠干燥30分钟,过滤,母液浓缩至400毫升;加热至43±2℃,搅拌下加入43±2℃的95%乙醇320g;将49克二水合草酸加入166g 95%乙醇中,搅拌溶清后,控温45±1℃将该溶液缓慢滴入上述步骤所得体系中,逐渐析出大量固体;保温45±1℃搅拌析晶30分钟,降至10±2℃,搅拌30分钟,过滤,滤饼分别以乙酸乙酯/乙醇=1/1的溶液约20g和甲基叔丁基醚20g洗涤,收集滤饼得湿品约78g;在20±2℃下真空烘干12小时,得白色固体72.8g, 收率50.8%。
以上实施例仅为本发明部分实施例,不能以此来限定本发明之权利范围,依据本发明所作等同变化,仍属本发明所涵盖的范围。
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110695178.2A CN115504913A (zh) | 2021-06-23 | 2021-06-23 | 一种阿维巴坦钠中间体的合成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110695178.2A CN115504913A (zh) | 2021-06-23 | 2021-06-23 | 一种阿维巴坦钠中间体的合成方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115504913A true CN115504913A (zh) | 2022-12-23 |
Family
ID=84499909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110695178.2A Pending CN115504913A (zh) | 2021-06-23 | 2021-06-23 | 一种阿维巴坦钠中间体的合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115504913A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103649051A (zh) * | 2011-06-17 | 2014-03-19 | 阿斯利康(瑞典)有限公司 | 制备包括反-7-氧代-6-(磺基氧基)-1,6-二氮杂二环[3,2,1]辛烷-2-甲酰胺的杂环化合物及其盐的方法 |
CN108264480A (zh) * | 2016-12-30 | 2018-07-10 | 上海星泰医药科技有限公司 | 阿维巴坦钠中间体的制备方法 |
CN109912499A (zh) * | 2017-12-12 | 2019-06-21 | 江苏奥赛康药业股份有限公司 | 阿维巴坦中间体及其制备方法 |
CN110498762A (zh) * | 2019-08-28 | 2019-11-26 | 齐鲁天和惠世制药有限公司 | 一种(2s,5r)-5-[(苄氧基)氨基]-哌啶-2-甲酸乙酯的合成方法 |
CN110590618A (zh) * | 2019-09-05 | 2019-12-20 | 江西富祥药业股份有限公司 | 一种阿维巴坦中间体的制备方法 |
-
2021
- 2021-06-23 CN CN202110695178.2A patent/CN115504913A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103649051A (zh) * | 2011-06-17 | 2014-03-19 | 阿斯利康(瑞典)有限公司 | 制备包括反-7-氧代-6-(磺基氧基)-1,6-二氮杂二环[3,2,1]辛烷-2-甲酰胺的杂环化合物及其盐的方法 |
CN108264480A (zh) * | 2016-12-30 | 2018-07-10 | 上海星泰医药科技有限公司 | 阿维巴坦钠中间体的制备方法 |
CN109912499A (zh) * | 2017-12-12 | 2019-06-21 | 江苏奥赛康药业股份有限公司 | 阿维巴坦中间体及其制备方法 |
CN110498762A (zh) * | 2019-08-28 | 2019-11-26 | 齐鲁天和惠世制药有限公司 | 一种(2s,5r)-5-[(苄氧基)氨基]-哌啶-2-甲酸乙酯的合成方法 |
CN110590618A (zh) * | 2019-09-05 | 2019-12-20 | 江西富祥药业股份有限公司 | 一种阿维巴坦中间体的制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111423452B (zh) | 瑞卢戈利的中间体及其制备方法和应用 | |
CN111320581A (zh) | 一种喹啉羧酸酯的合成方法 | |
CN109232470A (zh) | 一种合成氨噻肟酸的新工艺 | |
CN112047883B (zh) | 顺苯磺酸阿曲库铵的制备方法 | |
CN103864802A (zh) | 高纯度马来酸阿塞那平的制备方法 | |
CN111646998B (zh) | 一种伊布替尼的合成方法 | |
CN115504913A (zh) | 一种阿维巴坦钠中间体的合成方法 | |
CN102617335B (zh) | 一种对叔丁基苯甲酸的合成工艺 | |
CN105085510B (zh) | 一种(s)‑4‑氧代‑2‑(噻唑烷‑3‑羰基)吡咯烷‑1‑羧酸叔丁酯的制备方法 | |
CN103539745B (zh) | 一种塞克硝唑的制备方法 | |
CN113773322B (zh) | 一种Filgotinib的制备方法 | |
CN114195844B (zh) | 一种去氢表雄酮的制备方法 | |
CN113717063B (zh) | 一种妥洛特罗的制备及纯化方法 | |
CN114671859A (zh) | 一种瑞舒伐他汀钙及其中间体的制备方法 | |
CN113461508B (zh) | 一种α-酮苯丙氨酸钙的制备方法 | |
CN110698381A (zh) | 一种一锅两相法合成n-(苄氧羰基)琥珀酰亚胺的方法 | |
CN115124473B (zh) | 西咪替丁有关物质b的合成方法 | |
CN112661719B (zh) | 一种氨噻肟酸的清洁制备工艺 | |
CN116396330B (zh) | 一种环丙基取代的2h-苯并吡喃衍生物的制备方法 | |
CN114805412B (zh) | 一种制备双草酸硼酸锂的工艺 | |
CN108409701B (zh) | 一种二氢大豆苷元的制备方法 | |
CN113773235B (zh) | 一种氯舒隆的合成方法 | |
CN114835689B (zh) | 一种无溶剂制备厄贝沙坦的方法 | |
CN109956958B (zh) | 一种7-氨基-3-甲氧基甲基-3-头孢烯-4-羧酸合成方法 | |
CN109134385A (zh) | 一种尿嘧啶类化合物的纯化方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |